#Johannesburg #South Africa #IntelliGenome #CRISPR-TB #ILEX South Africa

IntelliGenome Partners with ILEX for CRISPR-TB Distribution in South Africa

IntelliGenome, Inc., a pioneering biotechnology firm specializing in CRISPR-based molecular diagnostics, has recently chosen ILEX South Africa (Pty) Ltd. as its exclusive distributor for the innovative CRISPR-TB product within the South African market. This strategic partnership is poised to significantly advance tuberculosis (TB) diagnostics, a critical area of health management in a country recognized for its substantial contributions to TB research and clinical innovation.

A New Era of TB Diagnostics

CRISPR-TB is an advanced, proprietary molecular assay developed by IntelliGenome, specifically designed for the detection of Mycobacterium tuberculosis complex cell-free DNA in blood samples. This revolutionary diagnostic tool represents a shift towards more effective tuberculosis testing, offering faster and potentially more accurate results compared to traditional methods. Given that South Africa is known for its leadership in TB research, the introduction of CRISPR-TB aligns perfectly with national healthcare priorities, aiming to enhance the detection of TB cases that often go unrecognized.

In support of the South African National TB Recovery Plan and the National Strategic Plan, this collaboration aims to expand access to advanced molecular diagnostics. These plans emphasize the necessity to identify absent TB cases, facilitate improved treatment outcomes, and strengthen preventative measures against TB, a disease that continues to have devastating effects on public health.

Strengthening TB Detection and Response

Kurt Wehrle, Vice President of Partnerships and Strategic Alliances at IntelliGenome, expressed optimism about this partnership, stating, “South Africa has consistently led the world in tuberculosis research and innovation. Together with ILEX, we look forward to supporting South Africa’s efforts to improve TB detection and expand access to advanced molecular diagnostics.” This collaboration not only highlights the trust IntelliGenome places in ILEX but also the commitment both entities have to addressing TB more efficiently.

ILEX will take the reins in introducing CRISPR-TB across South Africa, focusing on regulatory registration, market development, and providing essential technical support. The company also intends to foster scientific collaborations with local tuberculosis researchers and healthcare institutions. Shameera August, the CEO of ILEX South Africa, remarked, “We are pleased to partner with IntelliGenome to help advance blood-based tuberculosis diagnostics in South Africa. We look forward to working with clinicians, researchers, and healthcare institutions to expand access to CRISPR-TB throughout South Africa.”

About IntelliGenome

IntelliGenome is synonymous with cutting-edge molecular diagnostics, concentrating efforts on developing and commercializing innovative CRISPR-based technologies. Their commitment to combatting tuberculosis includes the global evaluation of the CRISPR-TB platform through partnerships with clinical, academic, and public health organizations. By advancing both laboratory-based and near-patient testing solutions, IntelliGenome aims to broaden the accessibility of tuberculosis diagnostics worldwide.

About ILEX South Africa

Founded in 1992, ILEX South Africa (Pty) Ltd is a foremost provider in the field of in vitro diagnostics (IVD), serving with advanced molecular diagnostics and laboratory solutions. Based in Johannesburg, with operations extending into 16 additional African nations, ILEX collaborates with top-tier healthcare institutions, clinical laboratories, and research bodies to provide cutting-edge diagnostic technologies backed by comprehensive regulatory and technical support.

Conclusion

The collaboration between IntelliGenome and ILEX South Africa underscores a crucial step forward in the fight against tuberculosis. By leveraging innovative molecular diagnostics, this partnership aims to make significant contributions to TB research and patient care, reinforcing South Africa's leading role in addressing this global health challenge.